Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma

发表于前天 16:38

期刊：Journal of Clinical Oncology

文献作者：Caroline Robert; Matteo S. Carlino; Catriona McNeil; Antoni Ribas; Jean-Jacques Grob; Jacob Schachter; Marta Nyakas; Damien Kee; Teresa M. Petrella; Arnold Blaustein; Michal Lotem; Ana Arance; Adil I. Daud; Omid Hamid; James Larkin; James Anderson; Clemens Krepler; Dmitri Grebennik; Georgina V. Long

出版日期：2023-8-20

DOI号：10.1200/jco.22.01599

下载链接：https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.01599

文献链接：https://doi.org/10.1200/jco.22.01599

当前文献来源于 American Society of Clinical Oncology (ASCO)。

备注信息：

发表于前天 16:58

: 当前求助处于待确认状态,请尽快下载
如果48小时后该求助仍未采纳，系统将自动采纳。

[ASCO] Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[ASCO] Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma 一键复制

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[ASCO] Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma